Biological E Gets Drug Regulator's Approval For Phase 2nd, 3rd Trial On Children
NDTV
The Drug Controller General of India (DCGI) granted permission to Hyderabad-based Biological E Limited to conduct Phase 2 and 3 clinical trials for its anti-COVID shots.
The Drug Controller General of India (DCGI) on Wednesday granted permission to Hyderabad-based Biological E Limited to conduct Phase 2 and 3 clinical trials for its anti-COVID shots called Corbevax on children between 5 and 18 years of age with certain conditions, sources told ANI. The trial will be conducted in ten locations. The permission has been given to Biological E after the recommendation from the Subject Expert Committee. Meanwhile, Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D has already received emergency use authorisation (EUA) to inoculate children in the age group of 12-18. It is expected to be administered from the first week of October.More Related News